Appendix Table 2.
Dysphagia, pneumonia, and stricture regressed on single modality treatments in multivariable models.
| Dysphagia No. pts (%), OR (95% CI) |
Stricture No. pts (%), OR (95% CI) |
Pneumonia No. pts (%), OR (95% CI) |
Aspiration
pneumonia No. pts (%), OR (95% CI) |
|||||
|---|---|---|---|---|---|---|---|---|
| Treatment Modality | ||||||||
| Radiation alone | 1,666/4,130 (40.3) | 1.81 (1.54–2.13) | 335/4,130 (8.1) | 1.42 (1.03–1.94) | 1,118/4,130 (27.1) | 1.27 (1.05–1.53) | 335/4,130 (8.1) | 1.34 (0.99–1.81) |
| Surgery alone | 1,109/4,147 (26.7) | -Ref- | 193/4,147 (4.7) | -Ref- | 800/4,147 (19.3) | -Ref- | 208/4,147 (5.0) | -Ref- |
| Race/Ethnicity | ||||||||
| Other | 111/365 (30.4) | 1.25 (0.93–1.68) | NR | 1.20 (0.87–1.67) | 83/365 (22.7) | 1.10 (0.79–1.55) | 22/365 (6.0) | 1.20 (0.69–2.09) |
| Hispanic | 124/361 (34.4) | 1.21 (0.87–1.67) | NR | 1.41 (1.05–1.91) | 92/361 (25.5) | 1.03 (0.71–1.50) | 31/361 (8.6) | 1.58 (0.93–2.68) |
| Black | 197/435 (45.3) | 1.47 (1.11–1.95) | NR | 1.21 (0.94–1.56) | 117/435 (26.9) | 1.22 (0.89–1.67) | 37/435 (8.5) | 1.24 (0.75–2.07) |
| Caucasian | 2,343/7,116 (32.9) | -Ref- | NR | -Ref- | 1,626/7,116 (22.9) | -Ref- | 453/7,116 (6.4) | -Ref- |
| Age quartiles | ||||||||
| >79 | 1,006/2,887 (34.9) | 1.12 (0.92–1.35) | 158/2,887 (5.5) | 0.66 (0.47–0.94) | 796/2,887 (27.6) | 1.87 (1.49–2.35) | 245/2,887 (8.5) | 2.23 (1.48–3.35) |
| 74–79 | 637/1,919 (33.2) | 1.05 (0.86–1.29) | 138/1,919 (7.2) | 0.72 (0.50–1.04) | 430/1,919 (22.4) | 1.36 (1.06–1.73) | 127/1,919 (6.6) | 1.41 (0.90–2.20) |
| 69–74 | 694/2,141 (32.4) | 1.05 (0.86–1.28) | 125/2,141 (5.8) | 0.76 (0.53–1.08) | 454/2,141 (21.2) | 1.30 (1.02–1.65) | 117/2,141 (5.5) | 1.54 (1.00–2.38) |
| <69 | 438/1,330 (32.9) | -Ref- | 107/1,330 (8.1) | -Ref- | 238/1,330 (17.9) | -Ref- | 54/1,330 (4.1) | -Ref- |
| Disease sub-site | ||||||||
| Nasopharynx | 35/81 (43.2) | 0.96 (0.46–1.97) | NR | 1.10 (0.25–4.76) | 18/81 (22.2) | 0.70 (0.28–1.74) | NR | 1.28 (0.37–4.41) |
| Oropharynx | 170/336 (50.6) | 1.46 (1.13–1.88) | NR | 1.82 (1.18–2.80) | 77/336 (22.9) | 0.90 (0.66–1.21) | NR | 1.00 (0.62–1.61) |
| Larynx | 1,283/3,333 (38.5) | 1.08 (0.90–1.30) | NR | 1.59 (1.13–2.24) | 897/3,333 (26.9) | 1.38 (1.12–1.70) | NR | 1.14 (0.82–1.60) |
| Oral cavity | 1,110/3,622 (30.7) | -Ref- | NR | -Ref- | 720/3,622 (19.9) | -Ref- | NR | -Ref- |
| Missing | 177 | NR | 206 | NR | ||||
| Sex | ||||||||
| Female | 1,002/3,103 (32.3) | 1.16 (1.02–1.33) | 181/3,103 (5.8) | 1.07 (0.93–1.23) | 624/3,103 (20.1) | 0.80 (0.68–0.92) | 155/3,103 (5.0) | 0.70 (0.54–0.91) |
| Male | 1,773/5,174 (34.3) | -Ref- | 347/5,174 (6.7) | -Ref- | 1,294/5,174 (25.0) | -Ref- | 388/5,174 (7.5) | -Ref- |
| Comorbidity | ||||||||
| 2 | 599/1,475 (40.6) | 1.51 (1.27–1.79) | 99/1,475 (6.7) | 0.97 (0.69–1.36) | 525/1,475 (35.6) | 2.26 (1.88–2.71) | 144/1,475 (9.8) | 1.77 (1.31–2.39) |
| 1 | 804/2,152 (37.4) | 1.31 (1.13–1.52) | 160/2,152 (7.4) | 1.09 (0.82–1.45) | 582/2,152 (27.0) | 1.64 (1.39–1.93) | 173/2,152 (8.0) | 1.52 (1.15–2.01) |
| 0 | 1,372/4,650 (29.5) | -Ref- | 269/4,650 (5.8) | -Ref- | 811/4,650 (17.4) | -Ref- | 226/4,650 (4.9) | -Ref- |
| SEER stage | ||||||||
| Distant | 173/434 (39.9) | 1.97 (1.71–2.27) | 26/434 (6.00) | 2.00 (1.62–2.48) | 124/434 (28.6) | 1.55 (1.33–1.82) | 29/434 (6.7) | 2.13 (1.65–2.75) |
| Regional | 677/1,541 (43.9) | 1.46 (1.15–1.84) | 109/1,541 (7.1) | 1.66 (1.44–1.92) | 433/1,541 (28.1) | 1.46 (1.12–1.89) | 152/1,541 (9.9) | 1.24 (0.78–1.96) |
| In situ/Localized | 955/3,587 (26.6) | -Ref- | 173/3,587 (4.8) | -Ref- | 687/3,587 (19.2) | -Ref- | 160/3,587 (4.5) | -Ref- |
| Unstaged/Missing | 970 | 220 | 674 | 202 | ||||
| Total | 2,775/8277 (33.5) | 528/8277 (6.4) | 1,918/8,277 (23.2) | 543/8,277 (6.6) | ||||
NR, numbers of patients not reported for cells in which n≤11 observations contributed to the estimate.